Seppi K - Search Results

1

Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease.

Mahlknecht P, Pechlaner R, Boesveldt S, Volc D, Pinter B, Reiter E, Müller C, Krismer F, Berendse HW, van Hilten JJ, Wuschitz A, Schimetta W, Högl B, Djamshidian A, Nocker M, Göbel G, Gasperi A, Kiechl S, Willeit J, Poewe W, Seppi K. Mahlknecht P, et al. Among authors: seppi k. Mov Disord. 2016 Sep;31(9):1408-13. doi: 10.1002/mds.26637. Epub 2016 May 9. Mov Disord. 2016. PMID: 27159493 Free PMC article. Review.

2

[Dementia with Lewy bodies].

Ransmayr G, Wenning GK, Seppi K, Jellinger K, Poewe W. Ransmayr G, et al. Among authors: seppi k. Nervenarzt. 2000 Dec;71(12):929-35. doi: 10.1007/s001150050689. Nervenarzt. 2000. PMID: 11139988 Review. German.

3

Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease.

Ransmayr G, Seppi K, Donnemiller E, Luginger E, Marksteiner J, Riccabona G, Poewe W, Wenning GK. Ransmayr G, et al. Among authors: seppi k. Eur J Nucl Med. 2001 Oct;28(10):1523-8. doi: 10.1007/s002590100571. Eur J Nucl Med. 2001. PMID: 11685496

4

Riluzole in Huntington's disease (HD): an open label study with one year follow up.

Seppi K, Mueller J, Bodner T, Brandauer E, Benke T, Weirich-Schwaiger H, Poewe W, Wenning GK. Seppi K, et al. J Neurol. 2001 Oct;248(10):866-9. doi: 10.1007/s004150170071. J Neurol. 2001. PMID: 11697523 Clinical Trial.

5

Treatment options for depression and psychosis in Parkinson's disease.

Poewe W, Seppi K. Poewe W, et al. Among authors: seppi k. J Neurol. 2001 Sep;248 Suppl 3:III12-21. doi: 10.1007/pl00007821. J Neurol. 2001. PMID: 11697683 Review.

6

Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): placebo-controlled, polysomnographic case report.

Högl B, Seppi K, Brandauer E, Wenning G, Poewe W. Högl B, et al. Among authors: seppi k. Mov Disord. 2001 Nov;16(6):1177-9. doi: 10.1002/mds.1207. Mov Disord. 2001. PMID: 11748758 Clinical Trial.

7

Riluzole therapy in cervical dystonia.

Müller J, Wenning GK, Wissel J, Baldauf A, Seppi K, Brenneis C, Poewe W. Müller J, et al. Among authors: seppi k. Mov Disord. 2002 Jan;17(1):198-200. doi: 10.1002/mds.1200. Mov Disord. 2002. PMID: 11835465

8

Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD.

Schocke MF, Seppi K, Esterhammer R, Kremser C, Jaschke W, Poewe W, Wenning GK. Schocke MF, et al. Among authors: seppi k. Neurology. 2002 Feb 26;58(4):575-80. doi: 10.1212/wnl.58.4.575. Neurology. 2002. PMID: 11865135

9

Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease.

Jellinger KA, Seppi K, Wenning GK, Poewe W. Jellinger KA, et al. Among authors: seppi k. J Neural Transm (Vienna). 2002 Mar;109(3):329-39. doi: 10.1007/s007020200027. J Neural Transm (Vienna). 2002. PMID: 11956955

10

Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia.

Müller J, Wenning GK, Wissel J, Seppi K, Poewe W. Müller J, et al. Among authors: seppi k. J Neurol. 2002 Mar;249(3):300-4. doi: 10.1007/s004150200009. J Neurol. 2002. PMID: 11993530 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

395 results

Search Page